DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV

Information source: University of Washington
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Genital Herpes; HIV Infection

Intervention: valacyclovir (Drug); acyclovir (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: University of Washington

Official(s) and/or principal investigator(s):
Jared Baeten, MD, PhD, Principal Investigator, Affiliation: University of Washington
Anna Wald, MD, MPH, Study Director, Affiliation: University of Washington


To compare the effect of high-dose valacyclovir (1 gram orally twice daily) versus standard-dose acyclovir (400 mg orally twice daily) on the frequency of genital HSV reactivation and on plasma HIV-1 levels among HSV-2/HIV-1 co-infected individuals. The investigators hypothesize that high-dose valacyclovir will result in greater reduction in plasma HIV-1 and genital HSV reactivation.

Clinical Details

Official title: A Randomized, Open-label, Crossover Trial of the Effect of Dosing of Daily HSV-2 Suppressive Therapy on HSV Reactivation and Plasma HIV-1 Levels Among HIV-1/ HSV-2 Co-infected Persons

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

The Quantity of HIV-1 RNA in Plasma While on 400 mg Twice Daily of Acyclovir Versus 1000 mg Twice Daily of Valacyclovir.

The Genital HSV Shedding Rate While on 400 mg Twice Daily of Acyclovir Versus 1000 mg Twice Daily of Valacyclovir.

Secondary outcome:

The Effect of Valacyclovir 1 Gram Twice Daily Compared to Acyclovir 400 mg Twice Daily on the Percentage of Days With Genital Herpes Lesions.

The Effect of Valacyclovir 1 g Twice Daily Compared With Acyclovir 400 mg Twice Daily on the Quantity of Genital HSV Detected During Shedding Episodes.

The Safety of Valacyclovir 1 Gram Orally Twice Daily in HIV-1 Seropositive Persons.

Sub-Study: To Evaluate the Kinetics of Plasma HIV-1 Decline Over the First Three Days of High-dose Valacyclovir Administration.

Detailed description: We propose to conduct a randomized, open-label, cross-over study of 38 individuals who are HIV-1 seropositive and HSV-2 seropositive. Both men and women will be recruited for the study. Participants must not be on antiretroviral therapy and must not be planning to initiate antiretroviral therapy during the anticipated study period. Participants will be randomized 1: 1 to receive acyclovir 400 mg twice daily or valacyclovir 1000 mg twice daily. After 12 weeks on the initial treatment, each participant will be crossed over to the alternative treatment arm for 12 weeks. The treatment periods will be separated by a 2-week washout period. During the first four weeks of each treatment period (i. e. weeks 1-4 and weeks 15-18), participants will provide self-collected genital swabs daily for HSV DNA quantification. Each week during the entire study period plasma samples will be collected from participants for HIV-1 RNA quantification. Open-label acyclovir and valacyclovir will be used for this trial, as the primary outcome measures (genital HSV and plasma HIV-1) are unlikely to be influenced by knowledge of treatment assignment. However, laboratory staff performing plasma HIV-1 and genital HSV measurements will not be aware of treatment assignment. Optional Sub-Study A: Sub-study A will be offered to study participants. The purpose of sub-study A is to measure the effect of valacyclovir twice daily on plasma HIV-1 replication.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Age 18 years or older

- Documented HIV-1 seropositive

- Not on HIV-1 antiretroviral therapy nor planning to initiate antiretroviral therapy

during the study period

- Detectable HIV-1 plasma viral load

- HSV-2 seropositive as determined by western blot

- Not intending to move out of the area for the duration of study participation

- Willing and able to provide independent written informed consent

- Willing and able to undergo clinical evaluations

- Willing and able to take study drug as directed

- Willing and able to adhere to follow-up schedule

Exclusion Criteria:

- Known history of adverse reaction to acyclovir, valacyclovir, or famciclovir

- Planned open label use of acyclovir, valacyclovir, or famciclovir

- History of evidence of CMV disease

- Known medical history of seizures

- Known renal insufficiency, defined as serum creatinine greater than 1. 5 mg/dl

- AST or ALT greater than 3 times upper limit of normal

- Hematocrit less than 30 %

- Neutropenia, defined as absolute neutrophil count less than 1000

- Thrombocytopenia, defined as platelet count less than 75,000

- History of thrombotic microangiopathy

- For women, pregnancy as confirmed by a urine pregnancy test

- Any other condition which, in the opinion of the principal investigator, may

compromise the ability to follow study procedures and complete the study

Locations and Contacts

University of Washington Virology Research Clinic, Seattle, Washington 98122, United States
Additional Information

Starting date: December 2007
Last updated: January 18, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017